Bright Minds Biosciences Inc.
DRUG
CNSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -14.46% | -35.42% | -29.56% | -34.25% | -29.65% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -61.83% | -63.97% | -61.01% | -49.64% | -48.70% |
| Operating Income | 61.83% | 63.97% | 61.01% | 49.64% | 48.70% |
| Income Before Tax | 84.28% | 62.35% | 59.86% | 48.76% | 48.22% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 84.28% | 62.35% | 59.86% | 48.76% | 48.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 84.28% | 62.35% | 59.86% | 48.76% | 48.22% |
| EBIT | 61.83% | 63.97% | 61.01% | 49.64% | 48.70% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 86.49% | 65.63% | 65.55% | 60.90% | 64.26% |
| Normalized Basic EPS | 86.50% | 65.63% | 65.54% | 60.89% | 64.25% |
| EPS Diluted | 86.33% | 65.43% | 65.48% | 60.72% | 64.16% |
| Normalized Diluted EPS | 86.36% | 65.53% | 65.47% | 60.89% | 64.25% |
| Average Basic Shares Outstanding | 28.95% | 15.59% | 18.86% | 26.62% | 36.70% |
| Average Diluted Shares Outstanding | 33.31% | 16.83% | 20.19% | 26.62% | 36.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
